Literature DB >> 7150243

Studies, with a luminogenic peptide substrate, on blood coagulation factor X/Xa produced by mouse peritoneal macrophages.

U Lindahl, S O Kolset, J Bøgwald, B Osterud, R Seljelid.   

Abstract

The formation and secretion of coagulation Factor X/Xa by mouse peritoneal macrophages was studied with a luminogenic peptide substrate (S-2613; t-butyloxycarbonylisoleucylglutamyl-gamma-piperidylglycylarginylisoluminol). Amidolysis was quantified by measuring the light emitted during oxidation of isoluminol, released by Factor Xa. A lower detection limit of about 0.5ng of Factor Xa was established; the assay was linear with enzyme concentration up to at least 100ng/ml. Factor X was determined after treatment with the Factor X-activating component of Russell's-viper (Vipera russelli) venom. Macrophages, cultured in the absence of serum, released Factor X/Xa into the culture medium. The concentration of coagulation enzyme in the medium increased in an essentially linear fashion over a period of at least 3 days, at a rate corresponding to 6-8ng produced/24h per 10(6) cells. The ratio of Factor Xa/X+Xa varied from about 60 to 100%, showing that activation of Factor X to Xa is not prerequisite to release of the enzyme from the cells. Factor Xa activity was suppressed in the presence of warfarin [3-(alpha-acetonylbenzyl)-4-hydroxycoumarin; 12.5mug/ml of medium], but could be restored by adding vitamin K (0.1mug/ml) along with the warfarin. Cultures to which Sepharose beads containing covalently bound anti-(Factor X) antibodies had been added showed decreased amounts of free Factor X/Xa in the culture medium. The missing activity could be demonstrated by incubating the recovered conjugate with the substrate peptide S-2613. Factor Xa produced by the macrophages was efficiently inactivated by heparin in the presence of antithrombin, heparin with high affinity for antithrombin being more effective than the corresponding low-affinity species.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150243      PMCID: PMC1158578          DOI: 10.1042/bj2060231

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.

Authors:  B Osterud; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  A simplified method for cyanogen bromide activation of agarose for affinity chromatography.

Authors:  S C March; I Parikh; P Cuatrecasas
Journal:  Anal Biochem       Date:  1974-07       Impact factor: 3.365

3.  Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom.

Authors:  P A Lindquist; K Fujikawa; E W Davie
Journal:  J Biol Chem       Date:  1978-03-25       Impact factor: 5.157

4.  Tissue thromboplastin activity of isolated human monocytes.

Authors:  H Prydz; A C Allison
Journal:  Thromb Haemost       Date:  1978-06-30       Impact factor: 5.249

5.  A differential effect of low-affinity heparin on the inhibition of thrombin and factor Xa by antithrombin.

Authors:  B Nordenman; K Nordling; I Björk
Journal:  Thromb Res       Date:  1980 Feb 1-15       Impact factor: 3.944

6.  Structural features of Salmonella typhimurium lipopolysaccharide required for activation of tissue factor in human mononuclear cells.

Authors:  F R Rickles; P D Rick
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

7.  The structure of a beta-(1 leads to 3)-D-glucan from yeast cell walls.

Authors:  D J Manners; A J Masson; J C Patterson
Journal:  Biochem J       Date:  1973-09       Impact factor: 3.857

8.  Factor X activating enzyme from Russell's viper venom: isolation and characterization.

Authors:  W Kisiel; M A Hermodson; E W Davie
Journal:  Biochemistry       Date:  1976-11-02       Impact factor: 3.162

9.  Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII.

Authors:  U Seligsohn; B Osterud; S F Brown; J H Griffin; S I Rapaport
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

10.  Complete replacement of serum by albumin, transferrin, and soybean lipid in cultures of lipopolysaccharide-reactive B lymphocytes.

Authors:  N N Iscove; F Melchers
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  7 in total

1.  Effect of cyclosporine A on procoagulant activity in mononuclear blood cells and monocytes in vitro.

Authors:  E Carlsen; A C Mallet; H Prydz
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

2.  Thrombin and factor Xa enhance the production of interleukin-1.

Authors:  A Jones; C L Geczy
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

Review 3.  Thrombin in inflammation and healing: relevance to rheumatoid arthritis.

Authors:  R Morris; P G Winyard; D R Blake; C J Morris
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

4.  Bradykinin stimulates bone resorption and lysosomal-enzyme release in cultured mouse calvaria.

Authors:  G T Gustafson; U Lerner
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

5.  Human monocytes have prothrombin cleaving activity.

Authors:  N Hogg
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

6.  Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.

Authors:  M F Scully; V Ellis; N Shah; V Kakkar
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

7.  Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease.

Authors:  R Adány; Z Nemes; L Muszbek
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.